Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Contaminants and Errors01:16

Contaminants and Errors

143
Effective sample preparation is crucial for accurate and reliable laboratory analysis. During this process, two significant sources of error can arise: concentration bias from improper sample splitting and contamination caused by methods used to reduce particle size, such as grinding or homogenization. Identifying and minimizing these potential errors is crucial to ensuring the validity of the analysis.
Another key consideration is determining the appropriate number of samples required to...
143
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

198
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
198
Margin of Error01:27

Margin of Error

4.5K
The margin of error is also called the maximum error of an estimate. The margin of error is the maximum possible or expected difference between the observed sample parameter value and the actual population parameter value. For proportion, it is the maximum difference between the value of sample proportion obtained from the data and the true value of population proportion. As the true value of the population parameter is not known, the margin of error is calculated using the sample statistic.
4.5K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

289
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
289
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

270
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
270
Accuracy and Errors in Hypothesis Testing01:13

Accuracy and Errors in Hypothesis Testing

303
Hypothesis testing is a fundamental statistical tool that begins with the assumption that the null hypothesis H0 is true. During this process, two types of errors can occur: Type I and Type II. A Type I error refers to the incorrect rejection of a true null hypothesis, while a Type II error involves the failure to reject a false null hypothesis.
In hypothesis testing, the probability of making a Type I error, denoted as α, is commonly set at 0.05. This significance level indicates a 5%...
303

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Phase I design for partially ordered groups with late-onset toxicity.

Clinical trials (London, England)·2026
Same author

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.

JCO precision oncology·2026
Same author

Pertuzumab and Trastuzumab in Patients With <i>ERBB2/3</i>-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study.

JCO precision oncology·2026
Same author

Temsirolimus in Patients With Solid Tumors With <i>PIK3CA</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

JCO precision oncology·2026
Same author

Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).

Prostate cancer and prostatic diseases·2026
Same author

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

相关实验视频

Updated: Sep 13, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K

丰富生物标记设计的样本大小与时间到事件结果的测量误差

Siyuan Guo1, Susan Halabi1, Aiyi Liu2

  • 1Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.

Pharmaceutical statistics
|July 25, 2025
PubMed
概括
此摘要是机器生成的。

这项研究解决了针对个性化医疗的有针对性的临床试验中的挑战. 我们提出了一个新的样本大小公式,以调整生物标志物错误分类,提高丰富生物标志物研究的试验能力.

关键词:
生物标志物错误分类的错误分类丰富的设计丰富的设计.患病率的流行情况.样本的大小 样本大小

更多相关视频

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study
20:24

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study

Published on: January 31, 2014

16.6K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

5.0K

相关实验视频

Last Updated: Sep 13, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K
Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study
20:24

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study

Published on: January 31, 2014

16.6K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

5.0K

科学领域:

  • 生物标志物的发现和验证.
  • 临床试验的设计和方法.
  • 个性化医学和有针对性的疗法

背景情况:

  • 个性化医疗旨在根据患者子组量身定制治疗.
  • 有针对性的临床试验设计丰富了对生物标志物阳性患者的试验.
  • 组织样本的异质性可能导致生物标志物的错误分类和减少试验功率.

研究的目的:

  • 评估生物标志物错误分类对有针对性的临床试验功率的不利影响.
  • 提出和验证一个样本大小公式,以调整目标设计中的错误分类.
  • 提高生物标记驱动的临床试验的效率和可靠性.

主要方法:

  • 开发一种统计方法来调整样本大小,以避免生物标志物被错误分类.
  • 导出针对性临床试验设计的新型样本大小公式.
  • 将拟议的配方应用于癌和前列腺癌的两个III期临床试验.

主要成果:

  • 生物标志物的异质性显著影响了丰富的临床试验的统计能力.
  • 拟议的样本大小调整公式有效地纠正了错误分类的错误.
  • 调整的样本大小确保了在有针对性的试验中检测治疗效应的足够功率.

结论:

  • 准确的样本大小计算对于生物标志物丰富的临床试验至关重要.
  • 开发的方法提供了一个强大的方法来克服生物标志物异质性带来的挑战.
  • 这种方法可以改善个性化药物试验的设计和解释.